By Ed SilvermanJune 5, 2026
Pharmalot Columnist, Senior Writer
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda includes promenading with the official mascots, catching some live musical vibes, and looking in on the Pharmalot ancestor. We also hope to squeeze in yet another listening party, where the rotation will likely include this, this, this, this and this. And what about you? Summer is closing in so this may be an opportunity to book a getaway, find some fab beach gear, or compile a challenging reading list. You could hit the pause button and catch up on your naps. Or maybe there is time to hang with someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
Leaders at the U.S. Food and Drug Administration listened to criticisms and recommendations for how to move forward with a speedy drug review program put in place by former FDA commissioner Marty Makary, STAT tells us. The listening session, held on the FDA’s White Oak Campus, featured 17 speakers representing patient groups, drug companies, and academic organizations. Some had positive feedback, particularly those whose drugs have already been approved through the program. But most asked the agency to pause the program, and then bring it back through normal regulatory procedures that require public feedback.
